PubMed Daily Triage Digest — 2026-07-25

Run ID: 2026-07-25-attempt2-20260725T093341Z
Status: PARTIAL_SUCCESS
Window: 2026-07-24 → 2026-07-25 (CRDT)
Articles retained: 24 (6 HIGH · 18 STANDARD · 3 LOW counted only)

⚠️ Partial coverage: T3, T4, T5, T6, T9 had truncated esummary batches; fewer than 15 candidates confirmed reviewed for those topics. T2 (CBC/ML) returned 0 results from both primary and fallback queries.

🔴 HIGH PRIORITY

1. [PMID 42498742] AI-CDSS for Inherited Retinal Diseases — Nature Medicine Multicenter RCT ★★★

Score: 9/10 | Topics: AI/ML Diagnostics, Rare Diseases
Journal: Nature medicine | DOI: 10.1038/s41591-026-04545-w
Authors: Jia H, Qian B, Qu Y, Wang J, Chen J, Li T, Zheng C, Han J, et al.
Flag: 🟢 NEAR_TERM_IMPLEMENTABLE | Design: Multicenter RCT (n=295) | Priority: HIGH

Key finding: Retina4IRD AI decision support system improved top-5 genetic accuracy from 67.3% to 88.5% for inherited retinal disease diagnosis (p<0.001); management decision score also significantly higher (37.7 vs 28.5, p<0.001).

Summary: First multicenter RCT (3 countries, NCT06839170) demonstrating an AI-CDSS using Vision Transformer + fundus/OCT imaging significantly improves rare retinal disease genetic diagnosis. Tool validated across China, South Korea, and Poland with external validation accuracy 0.856. Ready for pre-genetic-testing clinical workflow integration.

2. [PMID 42498680] MRD Dynamics + CAR-T Interception in Multiple Myeloma — Blood ★★★

Score: 8/10 | Topics: Hematologic Malignancies, Novel Therapeutics
Journal: Blood | DOI: 10.1182/blood.2026033878
Authors: Gonzalez C, Guerrero C, Larrayoz M, Zabaleta A, Zhao J, Terpos E, Rodriguez-Otero P, et al.
Flag: 🟠 NOVEL_TREATMENT | Design: Prospective cohort + multiomics + preclinical (n=539+249) | Priority: HIGH

Key finding: 5 MRD dynamics subgroups from 3,610 serial assessments outperform R-ISS staging; anti-BCMA CAR-T administered at MRD resistance prolonged survival vs identical treatment at relapse in preclinical models.

Summary: Comprehensive analysis of GEM trials (n=788 total) demonstrating that serial MRD dynamics outperform current staging in myeloma prognostication, identifying a "vulnerable window" at MRD resistance for CAR-T interception before full relapse. Multiomics reveals T-cell exhaustion and genomic evolution during MRD resistance. Reframes treatment timing strategy in myeloma.

3. [PMID 42498740] Liquid Biopsy-Based Antitumour Immunity Framework — Nat Rev Clin Oncol ★★★

Score: 8/10 | Topics: Early Cancer Detection, Precision Oncology
Journal: Nature reviews. Clinical oncology | DOI: 10.1038/s41571-026-01181-8
Authors: Pantel K, Masmoudi D, Alix-Panabières C
Flag: 🔴 EARLY_CANCER_DETECTION | Design: Expert review | Priority: HIGH

Key finding: Proposes comprehensive liquid biopsy framework integrating CTC, EV, cfDNA, and circulating immune cells to characterize antitumour immunity for immunotherapy monitoring and early detection.

Summary: Landmark review by field founders Pantel and Alix-Panabières in Nature Reviews Clinical Oncology proposing immune-based liquid biopsy as a next paradigm beyond cell-free DNA alone. Framework addresses the critical gap in non-invasive immunotherapy response monitoring and early cancer immune surveillance.

4. [PMID 42498285] Phase 1/1b All-Oral CC-486 + Venetoclax in AML — Blood Advances ★★

Score: 7/10 | Topics: Hematologic Malignancies, Novel Therapeutics
Journal: Blood advances | DOI: 10.1182/bloodadvances.2026020179
Authors: Amaya ML, Abbott D, McMahon CM, ... Jordan CT, Pollyea DA
Flag: 🟠 NOVEL_TREATMENT | Design: Phase 1/1b dose-escalation | Priority: HIGH

Key finding: All-oral CC-486 (oral azacitidine) plus venetoclax demonstrated safety/tolerability with preliminary antileukemic activity in AML; recommended Phase 2 dose established.

Summary: First fully oral HMA/BCL-2 inhibitor combination for AML from Pollyea group (CU Denver). Potential to eliminate IV/SC administration burden for elderly and unfit AML patients if Phase 2 confirms efficacy. Blood Advances.

5. [PMID 42498485] Triplet Immunotherapy TGF-β/PD-L1/tumor antigen + IL-15 in mCRPC — J Immunother Cancer ★★

Score: 7/10 | Topics: Novel Therapeutics
Journal: Journal for immunotherapy of cancer | DOI: 10.1136/jitc-2026-015336
Authors: Redman JM, Madan RA, Donahue RN, ... Schlom J, Gulley JL
Flag: 🟠 NOVEL_TREATMENT | Design: Early-phase NCI trial | Priority: HIGH

Key finding: Durable responses achieved with triplet immunotherapy (bintrafusp alfa + tumor antigen vaccine + ALT-803 IL-15 superagonist) in MMR-proficient castration-resistant prostate cancer — an immunotherapy-resistant disease.

Summary: NCI study demonstrating that simultaneously targeting TGF-β immunosuppression, PD-L1 checkpoint, tumor antigen expression, and NK/T-cell activation via IL-15 superagonism produces durable responses in MMR-proficient mCRPC where standard checkpoint inhibition fails. Schlom/Gulley group (CCR/NCI).

6. [PMID 42498486] VENEZOLUNG: Personalized DC Vaccination + Atezolizumab in ES-SCLC Phase Ib-II — J Immunother Cancer ★★

Score: 7/10 | Topics: Novel Therapeutics
Journal: Journal for immunotherapy of cancer | DOI: 10.1136/jitc-2026-015351
Authors: Gonzalez-Cao M, Sisteré-Oró M, Moran T, ... Rosell R, Benitez-Ribas D
Flag: 🟠 NOVEL_TREATMENT | Design: Phase Ib-II single-arm trial | Priority: HIGH

Key finding: Personalized tumor-loaded monocyte-derived dendritic cell vaccination + atezolizumab as maintenance in ES-SCLC demonstrated safety and preliminary efficacy in the VENEZOLUNG trial.

Summary: Proof-of-concept Phase Ib-II trial of autologous tumor-loaded DC vaccination combined with atezolizumab as ES-SCLC maintenance. Addresses dismal post-response prognosis; personalized vaccination approach supported by Spanish multicenter oncology consortium (Rosell R, Benitez-Ribas D).

🟡 STANDARD PRIORITY (Score 5–7)

7. [PMID 42498280] MCL Molecular Biomarkers — FIL V-RBAC Trial · Score 7

Journal: Blood advances | Topics: Hematologic Malignancies
Authors: Moia R, ... Gaidano G, Visco C | Flag: 🟢 NEAR_TERM_IMPLEMENTABLE
Prospective FIL multicenter trial analysis showing SOX11, TP53, MYC, and cell-of-origin are key outcome determinants in MCL. Supports biomarker-driven treatment stratification in this heterogeneous lymphoma.

8. [PMID 42498281] Long-Term Venetoclax Outcomes in Relapsed CLL · Score 7

Journal: Blood advances | Topics: Hematologic Malignancies
Authors: McKeague S, Lew TE, Lowe A, ... Roberts AW, Anderson MA | Flag: 🟢 NEAR_TERM_IMPLEMENTABLE
Long-term follow-up of continuous venetoclax in relapsed CLL (Peter MacCallum group) characterizing durable response kinetics, late relapse patterns, and resistance mechanisms including BCL-2 mutations and clonal evolution. Directly informs post-venetoclax sequencing decisions.

9. [PMID 42498483] irSAEs Do Not Predict Survival in dMMR/MSI-H Cancers — 34-Center n=1,175 · Score 7

Journal: Journal for immunotherapy of cancer | Topics: Novel Therapeutics
Authors: Tougeron D, Kauffmann C, ... Hollebecque A, et al. | Flag: 🟢 NEAR_TERM_IMPLEMENTABLE
Largest multicenter study (n=1,175, 34 centers) definitively showing severe irAEs are NOT independently associated with PFS or OS in dMMR/MSI-H digestive cancers treated with ICI, despite higher ORR. Practice-informing negative result.

10. [PMID 42498959] SGLT2 Inhibitors Reduce N4-Acetylcytidine (Vascular Damage Biomarker) — RCT · Score 7

Journal: Cardiovascular diabetology | Topics: Cardiometabolic
Authors: Gessner A, Kannenkeril D, ... Schmieder RE, Maas R | Flag: ⬜ NONE
RCT demonstrating dapagliflozin and empagliflozin significantly reduce plasma N4-acetylcytidine, a novel vascular endothelial damage biomarker, in diabetic atherosclerosis patients. New mechanistic pathway for SGLT2 vascular protection.

11. [PMID 42498061] Heterogeneous GLP-1RA Kidney Effects — n=28,547 Target Trial Emulation · Score 7

Journal: Kidney international | Topics: Cardiometabolic
Authors: Xu Y, Maas CCHM, ... Fu EL, Carrero JJ | Flag: 🟢 NEAR_TERM_IMPLEMENTABLE
Large target trial emulation (n=28,547; causal survival forests + KFRE) showing GLP-1RA kidney protection is concentrated in highest-risk patients (HR 0.70). Key predictors: low eGFR, fast eGFR decline, high albuminuria, high HbA1c. Actionable personalized prescribing guidance.

12. [PMID 42497096] Aspirin Does Not Improve Healthspan in Elderly — ASPREE RCT · Score 7

Journal: Age and ageing | Topics: Aging, Longevity
Authors: Zheng HT, Phyo AZZ, Wu Z, ... Woods R, Ryan J | Flag: ⬜ NONE
ASPREE multicenter RCT secondary analysis using a composite 'healthspan' endpoint confirms aspirin provides no net healthy longevity benefit in community-dwelling adults ≥70 years. Reinforces guidelines against routine aspirin primary prevention in elderly; introduces healthspan as a composite aging trial endpoint.

13. [PMID 42498179] Shwachman-Diamond Syndrome Cytogenetics — 27-Year Italian Registry · Score 7

Journal: European journal of medical genetics | Topics: Hematologic Malignancies, Rare Diseases
Authors: Micheloni G, Frattini A, ... RI-SDS working Group, Pasquali F, Valli R | Flag: ⬜ NONE
Landmark 27-year Italian registry characterizing cytogenetic clonal evolution, MDS/AML transformation risk, and evidence-based surveillance intervals in Shwachman-Diamond syndrome. Largest single-country SDS cytogenetics dataset.

14. [PMID 42498283] Real-Time Comprehensive Molecular Testing in LBCL · Score 6

Journal: Blood advances | Topics: Hematologic Malignancies, Rare Diseases
Authors: Chihara D, Balakrishnan K, ... Green MR, Fowler NH, Flowers CR, Westin JR | Flag: 🟢 NEAR_TERM_IMPLEMENTABLE
MD Anderson study demonstrating clinical utility of real-time molecular profiling (COO, genetic subgroups, TME) in LBCL for treatment selection including CAR-T eligibility planning.

15. [PMID 42498507] KRAS Mutations Predict Inferior Outcomes in MAPK-Mutated AML · Score 6

Journal: European journal of haematology | Topics: Hematologic Malignancies
Authors: Takaoka K, Mott S, ... Wannaphut C, Poonsombudlert K | Flag: ⬜ NONE
Retrospective analysis (n=74) showing KRAS mutation independently predicts inferior OS (HR 2.14) and RFS vs other MAPK mutations in newly diagnosed AML. Single-center, requires multicenter validation; relevant to emerging RAS inhibitor development.

16. [PMID 42498744] Chinese Expert Consensus on Pancreatic Cancer Precision Testing · Score 6

Journal: British journal of cancer | Topics: Early Cancer Detection, Precision Oncology
Authors: Cao D, Wu J, Cui J, ... Wang L, Qin S | Flag: 🟢 NEAR_TERM_IMPLEMENTABLE
Multidisciplinary Chinese expert consensus in Br J Cancer standardizing NGS testing, actionable mutations (KRAS, BRCA1/2, NTRK, MSI-H), liquid biopsy, and molecular therapy matching in pancreatic cancer. International-venue publication suggests global relevance.

17. [PMID 42498519] Exome Sequencing Yields in BRCA1/2-Negative Hereditary Cancer Families — n=500 · Score 6

Journal: Journal of medical genetics | Topics: Precision Oncology
Authors: Dell'Elice A, Palmarini C, ... Stuppia L, Antonucci I | Flag: 🟢 NEAR_TERM_IMPLEMENTABLE
Retrospective Italian cohort (n=500) demonstrating clinical exome sequencing identifies actionable pathogenic variants (PALB2, ATM, CHEK2, CDH1) beyond BRCA1/2 in hereditary cancer families. Supports expanded genetic testing implementation.

18. [PMID 42498467] SGLT-2/GLP-1RA Access Disparities Across 10 Countries · Score 6

Journal: BMJ open | Topics: Cardiometabolic
Authors: Li Z, Zhang S, Liu B | Flag: 🟡 UNDERSERVED_POPULATION
Cross-sectional 10-country analysis documenting major SGLT-2/GLP-1RA affordability gaps in LMICs despite high cardiometabolic burden. Highlights urgent health policy gap for globally proven therapies.

19. [PMID 42497841] Patients/Families Use GenAI in Rare Diseases — Mixed Methods Survey · Score 4

Journal: Journal of participatory medicine | Topics: AI/ML Diagnostics, Rare Diseases
Authors: Blease C, Jones J, Blease CE, Kharko A, Garcia Sanchez C, Mandl KD | Flag: ⬜ NONE
Exploratory survey documenting widespread generative AI use for information/support in rare disease communities, with concerns about accuracy and desire for clinical guidance. Mandl KD (Boston Children's/Harvard).

20. [PMID 42498511] ML for Transfusion Management in AML — Review · Score 5

Journal: Transfusion medicine | Topics: Hematologic Malignancies, CBC/ML
Authors: Li J, An X, Jing Z, Li Y | Flag: ⚪ PROMISING_PRELIMINARY
Review of multimodal ML models for AML transfusion decision support; bridges T1 and T2 watchlist topics. T2 vacant today; this review partially fills the CBC/ML signal gap.

21. [PMID 42498816] Invasive Pneumococcal Disease Unmasks MGUS — Multicenter Prospective · Score 5

Journal: Scientific reports | Topics: Hematologic Malignancies
Authors: Härnqvist T, Bergman K, ... Karlsson J, Skovbjerg S | Flag: ⬜ NONE
Multicenter prospective Swedish study establishing IPD as a clinical trigger for opportunistic MGUS and antibody deficiency screening. Clinically actionable early myeloma detection strategy.

22. [PMID 42498885] MRD and Leukemic Stem Cell Biology Review · Score 5

Journal: Stem cell reviews and reports | Topics: Hematologic Malignancies
Authors: Bhartiya D, Jha N, Dutta S, Tripathi A, Tripathi A | Flag: ⬜ NONE
Conceptual review on why MRD negativity does not equal cure (leukemic stem cell quiescence, drug resistance, immune evasion). Contextualizes alongside Blood MRD dynamics paper (PMID 42498680).

23. [PMID 42498824] Distinct Brain Circuits for GIPR Agonism vs Antagonism — Nat Metab · Score 5

Journal: Nature metabolism | Topics: Cardiometabolic
Authors: Lewis JE, Montaner M, Nuzzaci D, ... Gribble FM, Reimann F | Flag: ⚪ PROMISING_PRELIMINARY
Preclinical mechanistic study (score capped at 5 per non-human study rule) distinguishing hindbrain vs hypothalamic circuits for GIPR agonism vs antagonism, relevant to tirzepatide GLP-1/GIP dual agonist mechanism. Cambridge group (Reimann F); Nat Metab impact.

24. [PMID 42498470] Population-Level Frailty Index from Quebec Administrative Data · Score 5

Journal: BMJ open | Topics: Aging, Longevity
Authors: Dahel H, Williamson D, Li Q, ... Emond JP, Wang HT | Flag: ⬜ NONE
Retrospective validation of population-level frailty index from Quebec provincial administrative data (no clinical assessment required). Practical tool for aging population health surveillance and resource planning.

🔵 LOW (Counted Only — Not Included Above)

📊 Coverage Summary by Topic

T2 NOTE: Both primary and fallback queries returned 0 results for 2026-07-25 window.
PARTIAL_SUCCESS reason: esummary API responses truncated for multiple topics. All truncated batches used 5-PMID chunks per protocol; retry on next attempt will re-fetch missing PMIDs.

Generated by PubMed Triage Agent v1.3 · Attempt 2/3 · 2026-07-25T09:33:41Z